Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05812_nanopub.RANkXqh_U3nd18T-jInL2mVkeY5PT_z_mLQ7ryaJLA7Ds#assertion>. }
Showing items 1 to 20 of
20
with 100 items per page.
- drugbank:DB05812 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05812 label "Abiraterone [drugbank:DB05812]" assertion.
- drugbank:DB05812 seeAlso DB05812 assertion.
- drugbank:DB05812 seeAlso abiraterone.html assertion.
- drugbank:DB05812 seeAlso zytiga-drug.htm assertion.
- drugbank:DB05812 identifier "drugbank:DB05812" assertion.
- drugbank:DB05812 description "Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011." assertion.
- drugbank:DB05812 title "Abiraterone" assertion.
- drugbank:DB05812 bio2rdf_vocabulary:identifier "DB05812" assertion.
- drugbank:DB05812 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05812 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05812" assertion.
- drugbank:DB05812 bio2rdf_vocabulary:x-identifiers.org DB05812 assertion.
- drugbank:DB05812 drugbank_vocabulary:drugbank-id "DB05812" assertion.
- drugbank:DB05812 drugbank_vocabulary:x-cas cas:154229-19-3 assertion.
- drugbank:DB05812 drugbank_vocabulary:x-ahfs ahfs:10:00 assertion.
- drugbank:DB05812 drugbank_vocabulary:x-atc atc:L02BX03 assertion.
- drugbank:DB05812 drugbank_vocabulary:x-chebi chebi:68642 assertion.
- drugbank:DB05812 drugbank_vocabulary:x-kegg kegg:D09701 assertion.
- drugbank:DB05812 drugbank_vocabulary:x-wikipedia wikipedia:Abiraterone assertion.
- drugbank:DB05812 drugbank_vocabulary:x-ndc ndc:57894-150-12 assertion.